PLANNING INTERDISCIPLINARY STUDIES OF DIABETIC HEART: TECNOLOGY PLATFORM DVMT

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。技术平台开发：我们将参与建立一个技术平台的计划，以支持基本发现路径的活动。这些技术还将为以患者为导向的研究人员提供必要的复杂资源，以将发现转化为开发新的患者护理工具。这一平台将在华盛顿大学生物医学21的背景下开发。该平台将由技术中心的核心组成，这些技术中心配备有向基础和临床研究人员提供高通量分析技术、高度注释的患者样本和生物工具包集合的途径。这些资源将加快经过充分验证的生物标记物的开发，并促进开发新疗法所需的机械发现。技术平台中心将由发现号规划小组的专家成员在理事会的监督下开发和管理。相关中心有：高通量细胞筛选、翻译病理学、应用基因组学、代谢组学、纳米技术和蛋白质组学

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Technology Platform Development: We will engage in plan to establish a Technology platform to enable the activities of the Fundamental Discovery Pathways. The technologies will also provide the sophisticated resources necessary for the patient-oriented researchers to translate discovery to develop new tools for patient care. This platform will be developed within the context of BioMed 21 at Washington University. The Platform will be composed of cores of Technological Centers equipped to provide both basic and clinical investigators access to high-throughput assay technologies, highly annotated patient specimens, and collections of biological toolkits. These resources will expedite the development of well-validated biomarkers and facilitate the mechanistic discoveries necessary for development of novel therapeutics. The Technology Platform Centers will be developed and managed by expert members of the Discovery planning groups with oversight by the Council. Some relevant Centers are: High-Throughput Cell Screening, Translational Pathology, Applied Genomics, Metabolomics, Nanotechnology, and Proteomi